Objective: To establish a tobramycin dosing schedule for neonates of various gestational ages. Methods: This was a retrospective study with prospective validation. A retrospective study in 470 neonates, with suspected septicemia in the first week of life, was performed.
rum concentrations of aminoglycosides to maximize efficacy and minimize toxicity in adults.lm5 Efficacy of aminoglycosides is related to the ratio of peak serum concentration to the minimal inhibitory concentration (MIC) of the infecting microorganism and the area under the time versus concentration curve (AUC),iP5 whereas toxicity of these drugs seems to be related to high trough levels.rP5 On the basis of these pharmacodynamic characteristics and the results of clinical trials, it was recently advocated in three meta-analytic studies2P4S5 that aminoglycosides be administered once daily to adults.
Aminoglycosides also play an important role in the initial empiric treatment of neonatal septicemia. 6 Various regimens for dose, dosing interval, and monitoring have been suggested and imple-CLINICAL PHARMA COLOGY & THERAPEUTICS VOLUME 62, NUMBER 4 de Haag et al. 393
mented over the last two decades.7-14 A significant relation between gestational age and the need for prolonged dosing intervals was established, and the more recent dosing regimens propose once daily dosing of aminoglycosides in very low birth weight infants."-i5 However, we had the impression that high trough levels were frequently encountered in these infants even with once daily administration of aminoglycosides. We therefore performed this study to investigate the results of the dosing schedule we currently use to find a more appropriate dosing schedule to administer aminoglycosides to newborns of different gestational ages during the first week of life. Using population pharmacokinetics on our own data over the last few years, we established a dosing regimen that combined optimal efficacy with minimal toxicity. To validate this regimen, we prospectively tested it in our patient group.
PATIENTS AND METHODS
Patients. This retrospective study with prospective validation comprised all neonates in the first week of life who were treated with tobramycin as part of their empiric treatment for suspected neonatal sepsis in the neonatal intensive care unit of the Sophia Children's Hospital between August 1992 and December 1994. Only neonates whose paired peak and trough serum tobramycin levels were available were included. In the period between February and April 1997, additional patients were studied for validation.
Parameters. All parameters were abstracted from the patient files. Gestational ages and birth weights were recorded. Gestational age was determined on the basis of the mother's menstrual history, confirmed by early ultrasound examinations if available, and by physical examination with the use of the criteria of Dubowitz et a1.i6
Administration and dosage regimen of tobramycin.
Tobramycin was given in combination with 50 to 100 mg/kg/day amoxicillin (INN, amoxicilline) as empiric treatment for suspected neonatal sepsis. Patients with documented invasive bacterial infection received intravenous therapy for at least 10 days. Patients with sterile cultures and without a focus of infection received therapy for a total of 72 hours. Administration of tobramycin was done in a 30-minute intravenous infusion with the following dosing regimen: gestational age ~28 weeks, 3.5 mg/ kg/24 hours; gestational age from 28 to 36 weeks, 2.5 mg/kg/l8 hours; gestational age >36 weeks, 2.5 mg/ kg/12 hours. project group, University of California, San Francisco, Calif.). On the basis of the population estimates, individual empirical Bayes estimates were generated. Scatterplots against weight and age indicated that both clearance and volume of distribution were related to age and weight. After estimation of clearance per kilogram for birth weights, only a correlation between volume of distribution and age or weight remained (age and weight are naturally highly correlated in this group). The empirical Bayes estimates were used to calculate predicted peak and trough levels at steady state for different dose and dose interval combinations, and scatterplots against gestational age were constructed.
Target serum tobramycin levels were set. The target trough level was below 2 mg/L (generally accepted as trough when administering a drug more than once daily) and preferably below 1 rngL4,17 Target peak levels were set at a minimum of 5 mg/L dailyl'-'l and preferably 10 times the MIC of the infecting microorganism because of the possibility of emergence of aminoglycoside-resistant pathogens at lower ratios.21,22 The MIC of the most important gramnegative pathogen, Escherichia coli, is 1 mg/L in the Dutch population," so target peak levels were 5 to 10 mgn* Prospective study. The predictive performance of the dosing regimen was evaluated prospectively in patients receiving tobramycin according to the dosing recommendation mentioned in the results:
l Gestational age 132 weeks: 4 mgkg every 48 hours l Gestational age >32 weeks but <37 weeks: 4 mg/kg every 36 hours l Gestational age ~37 weeks: 4 mg/kg every 24 hours GA, Gestational age. Numbers are the number of patients; numbers in parentheses are the percentages of the total in the group.
Tobramycin peak and trough serum levels were determined 30 minutes after the first dose and just before the second dose and were analyzed as described in the retrospective study.
RESULTS
Retrospective study. Four hundred seventy neonates were enrolled in the study. Their gestational ages and birth weights ranged from 23 to 42 weeks (median age, 31.5 weeks) and from 485 to 5245 gm (median weight, 1530 gm), respectively. Table I summarizes the results of tobramycin peak and trough concentrations for the different gestational age groups. As shown in Table I , 19.1% of peak levels and 32.8% of trough levels were outside the desired therapeutic range. In the gestational age groups ~28 weeks and between 28 and 32 weeks, the percentage of aberrant trough levels was particularly high-48.8% and 38.3%, respectively.
On the basis of the scatterplots and set target serum tobramycm levels, the dosing is recommended at 4 mg/kg with the following dosing intervals: l Gestational age 532 weeks: 4 mg,ikg every 48 hours l Gestational age ~32 but ~37 weeks: 4 mg/kg every 36 hours l Gestational age ~37 weeks: 4 mgkg every 24 hours For illustrative purposes, the curves predicted with use of the advised dosing regimen and the empirical Bayes estimates were constructed and concentrations corresponding to the 5th, 50th, and 95th percentiles computed for the three dosing interval-age groups (Fig. 1) . Calculations were performed with SPSS for Windows (version 6.1.2). Fig. 2 and Table II show the predicted peak and trough levels with these recommendations. Fig. 2 clearly shows that predicted peak levels rose with gestational age. Predicted peak levels ranged from 2.9 to 18.7 mg/L, with a median of 8.0 mg/L. Predicted peak levels were below 5 mg/L in 4.9% of the newborns and above 10 mg/L in 27.9% of the newborns. Median peak levels in the gestational age groups were 6.1 mg/L in the group ~28 weeks old, 7.3 mg/L in the group aged between 28 and 32 weeks, 8.7 mg/L in the group aged between 32 and 37 weeks, and 13.2 in the term group. Insufficient peak levels were found in 11 of 82 (13.4%) of neonates with a gestational age ~28 weeks. Of these 11 newborns, 10 had predicted peak levels between 4 and 5 mg/L. Predicted trough levels ranged from 0.01 to 8.1 mg/L (median, 0.36 mg/L). Trough levels were above 2 mg/L in 1.9% of all patients and between 1 and 2 mg/L in 5.7%. As Fig. 2 shows, there was no relation between gestational age and trough levels. Fig. 1 shows the predicted serum levels over time for the three gestational age groups. The 50th percentile line of tobramycin serum levels dropped below 1 mg/L at approximately 18,24, and 32 hours in the groups that received tobramycin once every 24, 36, and 48 hours, respectively. Prospective study. Prospective evaluation was performed in 23 neonates. Their gestational ages ranged from 24.4 to 42.1 weeks (median, 32.5 weeks). Table III summarizes the results of observed tobramycin peak and trough concentrations for the different gestational age groups with use of the recommended dosing regimen. Peak levels ranged from 2.9 to 13.5 mg/L, with a median of 7.9 mg/L. Only one peak level was below 5 mg/L. Median peak levels in the gestational age groups were 6.9 mg/L in the group ~32 weeks old, 7.3 mg/L in the group aged between 32 and 37 de Ho08 et al. 395
weeks, and 9.0 in the term group. Trough levels were between 0.1 and 5.7 mg/L (median, 0.7 mg/L). High trough levels were found in seven patients. Of these, three patients had trough levels of 1.2 mg/L and one patient had a trough level of 1.3 mg/L. Median trough levels in the gestational age groups were 0.7 mg/L in the group ~32 weeks old, 0.65 mg/L in the group aged between 32 and 37 weeks, and 0.95 mg/L in the term group.
DISCUSSION
Earlier investigations of the pharmacokinetics of aminoglycosides and other drugs in neonates have shown that elimination half-lives are longer in neonates, especially in preterm neonates. 8-11'24 This is primarily the result of a higher percentage of body water and thus a larger volume of distribution and reduced clearance.25,26 Most dosing schedules for preterm and term neonates take this into account.7-12'14 We had the clinical impression that our use of gestational age-related dosing still led to serum concentrations that were frequently outside the desired range. The inventory of our own results over the past few years showed that about one third of the initial trough serum levels were too high, particularly in prematures neonates, and that in view of these results a more appropriate dosing schedule should be found.
The limitation of administration of aminoglycosides to neonates lies in the long elimination halflife; therefore the only way to effectively reduce trough serum levels without compromising adequate peak levels is by further increasing the dosing interval. It is difficult to define the desired therapeutic range for aminoglycosides. Peak levels of >4 to 5 mg/L are generally accepted as necessary for antibacterial efficacy with administration three times a daylgm21; however, questions are being raised about the underlying fundament of this assumption.3 What is known is that efficacy of aminoglycosides is related to the peak level/ MIC ratio and AUClT21 and that in vitro ratios of 10: 1 prevent emergence of aminoglycosideresistant pathogens.22 In the first week of life, the pathogens for which tobramycin is indicated as therapy are mainly acquired through the birth passage. By far the most common pathogen in this group of gram-negative bacteria is E. coli.27 In a recent survey of the Dutch population, the MIC,, for E. coli was found to be 1 mg/L, 23 Gestational age (wks) GA, Gestational age. Numbers are the number of patients; numbers in parentheses are the percentages of the total in the group.
would be optimal, a peak/MIC ratio of 5 can be considered to be effective. The effect of serum concentrations on toxicity is even harder to quantify. High aminoglycoside peak levels do not increase nephrotoxicity because of drug-specific saturable uptake. [28] [29] [30] In several large meta-analytical studies, toxicity seems to be related to high predose levels, indicating that trough levels are not low long enough to prevent renal accumulation."275'19 Commonly accepted trough level goals are <2 mg/L, but for once-a-day administration, most authors keep 1 mg/L as a safe limit.4'17 Another point in the discussion is that renal toxicity is mostly reversible, whereas ototoxicity is usually irreversible. Most authors suggest that ototoxicity is related to CLINICAL P HARMACOLOGY & THERAPEUTICS VOLUME 62, NUMBER 4 de Hoog et al. 397 total dose and duration of therapy rather than to serum aminoglycoside levels, but the relation to aminoglycoside serum levels remains unclear. This form of toxicity usually occurs in patients who have received either long or repeated courses of aminoglycosides.3 Reports about ototoxicity in neonates are contradictory. Some authors report no relation,31-33 whereas others did find a higher incidence.34-36 Until conclusive evidence is given, it seems prudent to keep the duration of tobramycin therapy as short as possible.
On the grounds of a peak/MIC ratio above 10 and the MIC,, of E. coli in our population, a peak tobramycin serum concentration as high as 10 mg/L is desirable from the efficacy point of view. A trough level below 1 mg/L will have to suffice until better data about toxicity are available.
Using population pharmacokinetics, we established a better dosing scheme to meet these criteria. This resulted in the following gestational agerelated regimen:
l Gestational age 132 weeks: 4 mg/kg/48 hours l Gestational age >32 weeks but ~37 weeks: 4 mg/kg/36 hours l Gestational age >37 weeks: 4 mg/kg/24 hours With this regimen most predicted peak levels were in the required range in neonates with a gestational age above 32 weeks, with acceptable predicted trough values for almost all (Table II) . In the gestational age group below 28 weeks, predicted peak serum levels were arguably too low in 12 of 82 patients, but 11 of these were between 4 to 5 mg/L. The prospective evaluation showed that serum peak levels were in the desired therapeutic range in all but one patient (Table III) . Measured trough levels were mildly elevated in four patients and clearly too high in three, so there is a definite need for measuring trough serum levels before the second dose. This dosing regimen also makes redundant the need for a loading dose of aminoglycosides in premature neonates, as suggested by some researchers,11,17,37 because high enough peak levels are achieved at the first dose. In addition, the practical advantage of this proposed schedule is a fixed starting dose per kilogram of body weight, irrespective of gestational age.
A possible problem in the group that received tobramycin once every 48 hours is that tobramycin levels might be subtherapeutic for too long. Twentyfour-hour serum levels in this group (Fig. 1) show that levels in most neonates were around 2 mg/L (which is still higher than the MIC of relevant microorganisms) but dropped below 1 mg/L after approximately 32 hours. In the prospective group of 23 patients, serum trough levels did not fall too low. Furthermore, there is also the post-antibiotic effect, or post-antibiotic leukocyte enhancement effect, or sub-MIC effect, which will prevent regrowth of bacteria at sub-MIC levels of tobramycin for another period of at least hours,38-40 so we consider this to be a safe dosing interval.
In conclusion, the information that we presented shows that acceptable therapeutic tobramycin peak and trough concentrations can be reached with a simple dosing schedule for three separate gestational age groups in the first week of life. Trough levels according to our scheme are not toxic and probably not long enough below 1 kg/ml to permit bacterial regrowth.
